Literature DB >> 30859683

Epigenetic therapy in hematological cancers.

Konstantinos Dimopoulos1,2, Kirsten Grønbaek1,2.   

Abstract

The increasing depth of knowledge about cancer biology throughout the last decades, has underlined the importance of not only genetic aberrations, but also epigenetic abnormalities in cancer cells. The extensive exploration of the cancer epigenome has provided insights into key pathways involved in tumorigenesis, as well as has allowed the development of novel epigenetic therapies. In this review, we will present the important role of epigenetic alterations in hematological diseases, with special focus on epigenetically-based targeting of hematological malignancies.
© 2019 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Epigenetics; hematology; leukemia; lymphoma; myeloma

Mesh:

Substances:

Year:  2019        PMID: 30859683     DOI: 10.1111/apm.12906

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

Review 1.  RNA methylation in hematological malignancies and its interactions with other epigenetic modifications.

Authors:  Lan Yao; Hua Yin; Mei Hong; Yajun Wang; Tingting Yu; Yao Teng; Tingting Li; Qiuling Wu
Journal:  Leukemia       Date:  2021-03-25       Impact factor: 12.883

Review 2.  The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Authors:  Mathias Boulanger; Rosa Paolillo; Marc Piechaczyk; Guillaume Bossis
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

3.  Editorial: Novel Drugs Targeting the Microenvironment and the Epigenetic Changes in Hematopoietic Malignancies.

Authors:  Diana Gulei; Ciprian Tomuleasa; Liren Qian; Cristina Bagacean; Carlo M Croce; Gabriel Ghiaur
Journal:  Front Pharmacol       Date:  2020-12-10       Impact factor: 5.810

4.  The effects of valproic acid on skin healing: experimental study in rats.

Authors:  Rachel Biondo-Simões; Maria de Lourdes Pessole Biondo-Simões; Sérgio Ossamu Ioshii; Rogério Ribeiro Robes; Moacir de Oliveira Dall'Antonia
Journal:  Acta Cir Bras       Date:  2022-07-15       Impact factor: 1.564

Review 5.  Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia.

Authors:  Wei-Wei Liu; Hao Wang; Xiao-Yu Zhu
Journal:  Biomark Res       Date:  2022-08-23

Review 6.  Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

Authors:  Catharina Muylaert; Lien Ann Van Hemelrijck; Anke Maes; Kim De Veirman; Eline Menu; Karin Vanderkerken; Elke De Bruyne
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

7.  Chinese Medicine Regulates DNA Methylation to Treat Haematological Malignancies: A New Paradigm of "State-Target Medicine".

Authors:  Feng-Lin Shen; Yan-Na Zhao; Xiao-Ling Yu; Bo-Lin Wang; Xiao-Long Wu; Gao-Chen Lan; Rui-Lan Gao
Journal:  Chin J Integr Med       Date:  2021-07-09       Impact factor: 1.978

Review 8.  Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.

Authors:  Nelson Montalvo; Jorge Lara-Endara; Ligia Redrobán; María Leiva; Christian Armijos; Leonardo Russo
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.